News - 13 Mar `24Lessons In Marketing: How To Sell A Disease To Big Pharma

New

Lessons In Marketing: How To Sell A Disease To Big Pharma

Seeing Incyte’s “See What’s Possible” campaign — complete with larger-than-life vitiligo models at the AAD meeting in San Diego — was a milestone for our community.

For years, vitiligo flew below the healthcare industry’s radar. Today, it’s front-and-center: the first FDA-approved therapy is on the market, and more than 40 companies are investing in vitiligo R&D.

That momentum didn’t appear by chance; it grew from steady advocacy, data-driven storytelling, and a lot of patient and caregiver voices refusing to be invisible.

It’s proof that even a small non-profit like VRF can help shift perceptions and priorities across an entire field. We’re even considering a white paper on the journey, with the working title “How to Bring an Overlooked Disease to Pharma’s Attention.”

If you’d like to contribute insights or client-side perspectives, let us know!

— Yan Valle

CEO, Vitiligo Research Foundation | Author, A No-Nonsense Guide to Vitiligo

Vitiligo marketing

AAD, 2024

AAD, 2025

 



      FAQOther Questions

      • Awareness Days Similar to World Vitiligo Day

        World Vitiligo Day, celebrated annually on June 25 since 2012, is a significant event dedicated to raising awareness about vitiligo and supporting those affected by the conditio...

      • What are risks of oral and topical corticosteroids?

        Corticosteroid drugs (like hydrocortisone, and others) are often used for treating vitiligo. By mimicing the effects of hormones your body produces naturally in your adrenal gla...

      • Is there a special diet for vitiligo?

        Recent research highlights the potential of diet and nutrition in managing vitiligo, offering an alternative where traditional therapies may be lacking. However, the relationshi...